|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
121,380,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Guardant Health is a precision oncology company focused on helping conquer cancer globally through use of its proprietary blood-based tests, data sets and analytics. Co. is engaged in the clinical liquid biopsy market with its Guardant360 and GuardantOMNI tests. Co.'s Guardant360 test is a molecular diagnostic test measuring a number of cancer-related genes and its GuardantOMNI test has a 500-gene panel, both of which analyze circulating tumor DNA in blood. In addition, Co. is developing tests from its LUNAR-1 program for minimal residual disease and recurrence detection in cancer survivors, and its LUNAR-2 program for early detection of cancer.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
2,187 |
2,187 |
5,168 |
98,220 |
Total Buy Value |
$38,963 |
$38,963 |
$136,461 |
$2,585,297 |
Total People Bought |
1 |
1 |
1 |
2 |
Total Buy Transactions |
1 |
1 |
2 |
4 |
Total Shares Sold |
100 |
6,000 |
10,991 |
31,616 |
Total Sell Value |
$1,905 |
$157,493 |
$334,111 |
$1,291,105 |
Total People Sold |
1 |
2 |
2 |
3 |
Total Sell Transactions |
1 |
3 |
6 |
11 |
End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Talasaz Amirali |
Chairman, President and COO |
|
2020-08-04 |
4 |
AS |
$83.89 |
$1,262,877 |
D/D |
(15,000) |
2,689,532 |
|
- |
|
Talasaz Amirali |
Chairman, President and COO |
|
2020-08-04 |
4 |
OE |
$4.18 |
$62,700 |
D/D |
15,000 |
2,704,532 |
|
- |
|
Talasaz Amirali |
Chairman, President and COO |
|
2020-08-03 |
4 |
AS |
$85.27 |
$5,175,768 |
D/D |
(60,000) |
2,689,532 |
|
- |
|
Talasaz Amirali |
Chairman, President and COO |
|
2020-08-03 |
4 |
OE |
$4.18 |
$250,800 |
D/D |
60,000 |
2,749,532 |
|
- |
|
Bertocci Derek A |
Chief Financial Officer |
|
2020-08-01 |
4 |
D |
$85.18 |
$60,819 |
D/D |
(714) |
61,473 |
|
- |
|
Saia John G. |
See Remarks |
|
2020-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
12,412 |
12,412 |
|
- |
|
Meresman Stanley J |
Director |
|
2020-07-10 |
4 |
AS |
$86.66 |
$519,960 |
D/D |
(6,000) |
4,059 |
|
- |
|
Meresman Stanley J |
Director |
|
2020-07-10 |
4 |
OE |
$5.94 |
$35,640 |
D/D |
6,000 |
10,059 |
|
- |
|
Talasaz Amirali |
Chairman, President and COO |
|
2020-07-06 |
4 |
AS |
$83.99 |
$1,691,001 |
D/D |
(20,108) |
2,689,532 |
|
- |
|
Talasaz Amirali |
Chairman, President and COO |
|
2020-07-06 |
4 |
OE |
$4.18 |
$84,051 |
D/D |
20,108 |
2,709,640 |
|
- |
|
Talasaz Amirali |
Chairman, President and COO |
|
2020-07-02 |
4 |
AS |
$83.48 |
$4,603,794 |
D/D |
(54,892) |
2,689,532 |
|
- |
|
Talasaz Amirali |
Chairman, President and COO |
|
2020-07-02 |
4 |
OE |
$4.18 |
$229,449 |
D/D |
54,892 |
2,744,424 |
|
- |
|
Kaul Samir |
Director |
|
2020-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,757 |
4,059 |
|
- |
|
Gadde Vijaya |
Director |
|
2020-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
4,703 |
4,703 |
|
- |
|
Meresman Stanley J |
Director |
|
2020-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,757 |
4,059 |
|
- |
|
Jallal Bahija |
Director |
|
2020-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,757 |
5,594 |
|
- |
|
Clark Ian T |
Director |
|
2020-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
3,341 |
4,643 |
|
- |
|
Meresman Stanley J |
Director |
|
2020-06-10 |
4 |
AS |
$80.59 |
$483,540 |
D/D |
(6,000) |
1,302 |
|
- |
|
Meresman Stanley J |
Director |
|
2020-06-10 |
4 |
OE |
$5.94 |
$35,640 |
D/D |
6,000 |
7,302 |
|
- |
|
Svf Endurance (cayman) Ltd |
|
|
2020-06-08 |
4 |
S |
$83.16 |
$96,673,500 |
D/D |
(1,162,500) |
14,037,960 |
|
- |
|
Svf Endurance (cayman) Ltd |
|
|
2020-06-04 |
4 |
S |
$83.16 |
$644,490,000 |
D/D |
(7,750,000) |
15,200,460 |
|
- |
|
Clark Ian T |
Director |
|
2020-06-03 |
4 |
AS |
$87.52 |
$235,429 |
D/D |
(2,690) |
1,302 |
|
- |
|
Clark Ian T |
Director |
|
2020-06-03 |
4 |
OE |
$4.18 |
$11,244 |
D/D |
2,690 |
3,992 |
|
- |
|
Talasaz Amirali |
Chairman, President and COO |
|
2020-06-03 |
4 |
AS |
$85.04 |
$4,709,402 |
D/D |
(55,000) |
2,689,532 |
|
- |
|
Talasaz Amirali |
Chairman, President and COO |
|
2020-06-03 |
4 |
OE |
$4.18 |
$229,900 |
D/D |
55,000 |
2,744,532 |
|
- |
|
671 Records found
|
|
Page 16 of 27 |
|
|